Category - Developments

Developments

Molteni acquires Titan Pharma’s European Probuphine IP

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a definitive asset purchase, supply and support agreement with closely-held L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. of Italy, through which...

March 22, 2018

Developments

Vital Therapies completes enrollment in VTL-308 pivotal trial

Vital Therapies’ (NASDAQ:VTL) VTL-308 Phase 3 trial to evaluate its cell-based therapy, ELAD, in subjects with severe alcoholic hepatitis has reached its enrollment target of 150 subjects. Subjects in VTL-308 were...

March 22, 2018

Developments

Scientus Pharma gains media awareneness

A Canadian Press piece appearing in several newspapers and broadcast news reports features closely-held Scientus Pharma and other companies as they look beyond legalization of recreational cannabis this summer to...

March 16, 2018

Developments

Ortho RTi gets European patent allowance protecting Ortho-R technology

Ortho Regenerative Technologies (CSE:ORTH) has received a notice of allowance from the European Patent Office that when issued, will provide intellectual property protection for the composition of matter of its Ortho-R...

March 8, 2018

Developments

Profound Medical upsizes bought deal financing from $20- to $30-million

Profound Medical (TSXV:PRN) has entered into an agreement with a syndicate of underwriters, led by Canaccord Genuity, to sell on a bought deal basis a total of 30 million units at a price of $1 each for gross proceeds...

February 28, 2018

Developments

VolitionRx reports positive interim Nu.Q diagnostic results in colorectal cancer

VolitionRx (NYSE American:VNRX) announced interim results from its first asymptomatic colorectal cancer (CRC) frontline screening study in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark, with...

February 27, 2018

Developments

Micromedic’s CellDetect detects prostate cancer cells in urine

Micromedic Technologies (TASE: MCTC) announced successful results of a clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology. The study included 59 urine samples (28...

February 26, 2018

Developments

RPS Diagnostics, Atomo in FebriDx pact

Closely-held RPS Diagnostics and Atomo Diagnostics of Australia have entered into a commercial and development partnership to create next generation FebriDx tests that are anticipated to transform the diagnosis of...

February 20, 2018

Developments

Scientus Pharma completes $15.8-million private placement

Closely-held Scientus Pharma has completed a private placement of common shares at a price of $4 each for gross proceeds of approximately $15.8-million. Net proceeds will be used for working capital and general...

February 16, 2018

Developments

Evotec, MaRS announce first LAB 150 project

Evotec AG (Frankfurt Stock Exchange:EVT) and MaRS Innovation announced the first project to be developed under their LAB150 partnership would target an unmet medical need in skin inflammatory conditions. The project...

February 15, 2018

Category - Developments

Subscribe